Abstract

The production of chiral amines by transaminase-catalyzed amination of ketones is an important application of biocatalysis in synthetic chemistry. It requires transaminases that show high enantioselectivity in asymmetric conversion of the ketone precursors. A robust derivative of ω-transaminase from Pseudomonasjessenii (PjTA-R6) that naturally acts on aliphatic substrates was constructed previously by our group. Here, we explore the catalytic potential of this thermostable enzyme for the synthesis of optically pure aliphatic amines and compare it to the well-studied transaminases from Vibrio fluvialis (VfTA) and Chromobacterium violaceum (CvTA). The product yields indicated improved performance of PjTA-R6 over the other transaminases, and in most cases, the optical purity of the produced amine was above 99% enantiomeric excess (e.e.). Structural analysis revealed that the substrate binding poses were influenced and restricted by the switching arginine and that this accounted for differences in substrate specificities. Rosetta docking calculations with external aldimine structures showed a correlation between docking scores and synthetic yields. The results show that PjTA-R6 is a promising biocatalyst for the asymmetric synthesis of aliphatic amines with a product spectrum that can be explained by its structural features.

Highlights

  • Pure amines are of great interest for the pharmaceutical and wider fine chemical industries as they can serve as intermediates in the preparation of a diversity of biologically active compounds [1,2,3]

  • Many ω-TAs and related enzymes are called amine transaminases (ATAs) as they act on substrates that lack a Catalysts 2020, 10, 1310; doi:10.3390/catal10111310

  • Whereas CvTA and Vf TA produced linear aliphatic amines with e.e.

Read more

Summary

Introduction

Pure amines are of great interest for the pharmaceutical and wider fine chemical industries as they can serve as intermediates in the preparation of a diversity of biologically active compounds [1,2,3]. Chiral amines are used as building blocks in the synthesis of pharmaceuticals used in the treatment of Alzheimer’s disease [4] and malaria [5] or as antitumor agents [6]. Transaminases (TAs) catalyze the transfer of amino groups from amines (amino donors) to aldehydes or ketones (amino acceptors), with pyridoxal-50 phosphate (PLP) as the cofactor (Scheme 1) [2,9]. Many ω-TAs and related enzymes are called amine transaminases (ATAs) as they act on substrates that lack a Catalysts 2020, 10, 1310; doi:10.3390/catal10111310 www.mdpi.com/journal/catalysts

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call